The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of biomarker guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on EGFR-mutation status.
Wenzhao Zhong
No relevant relationships to disclose
Xue-Ning Yang
No relevant relationships to disclose
Xuchao Zhang
No relevant relationships to disclose
Jian Su
No relevant relationships to disclose
Hong-Hong Yan
No relevant relationships to disclose
Zhihong Chen
No relevant relationships to disclose
Riqiang Liao
No relevant relationships to disclose
Qiang Nie
No relevant relationships to disclose
Song Dong
No relevant relationships to disclose
Yi-Long Wu
No relevant relationships to disclose